Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2019 Apr 8;18(6):1115–1126. doi: 10.1158/1535-7163.MCT-18-0743

Figure 6.

Figure 6.

HER2 levels post-treatment. PDX12 (a–e) and PDX8 (g–k) tumor sections were evaluated for HER2 via IHC. Representative HER2 IHC images are presented to compare treatment groups. Note PDX12 and PDX8 T-DM1-treated tumors express lower levels of HER2 (c–e and i–k). Note single agent ABT-263 upregulates HER2 in PDX12 tumors (b). HER2 was quantified via H-score assessment (37). Data were summarized across multiple tumors from PDX12 (f) and PDX8 (l) experiments (Mann-Whitney one-tail test PDX12: vehicle versus ABT-263; p value = 0.0500, vehicle versus T-DM1; p value = 0.0500, vehicle versus T-DM1 + ABT-263; p value = 0.0286, vehicle versus T-DM1 + PULSEABT-263; p value = 0.0286 and PDX8: vehicle versus T-DM1; p value = 0.0079, vehicle versus T-DM1 + ABT-263; p value = 0.0079, vehicle versus T-DM1 + PULSEABT-263; p value = 0.0179). p values ≤ 0.05 (*) or ≤ 0.01 (**) are indicated as numerical values. Each line represents the median. Scale bar, ~90 μm.